Dr. Yang Luo 罗扬
Chief Physician
Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences (National Cancer Center), Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical treatment of lung cancer, breast cancer, and gastrointestinal tumors.
Dr. Luo is a Chief Physician with a medical doctorate at the Cancer Hospital, Chinese Academy of Medical Sciences. Research focuses on medical oncology for lung, breast, and gastrointestinal cancers, including clinical analysis of rare tumors such as pulmonary sarcomatoid carcinoma and primitive neuroectodermal tumors. Dr. Luo has published over 40 papers and participated in multiple international and domestic multicenter clinical studies.
Name order: in Chinese the family name comes first (Luo Yang). Papers usually list the name as Yang Luo or Luo Y.
Selected publications
117 papers on PubMed matched by name and affiliation; 10 as first or senior author since 2016. Most recent first- or senior-author papers:
- Invest New Drugs, 2023 (first author): Pharmacokinetics, safety, and antitumor activity of talazoparib monotherapy in Chinese patients with advanced solid tumors. PubMed 37171721
- J Clin Lab Anal, 2022 (first author): Development of a novel five-lncRNA prognostic signature for predicting overall survival in elderly patients with breast cancer. PubMed 34894405
- Front Endocrinol (Lausanne), 2021 (first author): Combination of Endogenous Estradiol and Adipokine Leptin in Breast Cancer Risk and Prognosis Assessment in Postmenopausal Chinese Women. PubMed 34970222
- Cancer Manag Res, 2020 (senior author): Depth of Response and Early Tumor Shrinkage for Predicting Clinical Outcomes in HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab. PubMed 32982445
- Cancer Manag Res, 2020 (first author): Eradication of Hepatitis C Virus (HCV) Improves Survival of Hepatocellular Carcinoma Patients with Active HCV Infection - A Real-World Cohort Study. PubMed 32753950
- Drug Des Devel Ther, 2019 (senior author): Baseline Lymphopenia: A Predictor Of Poor Outcomes In HER2 positive Metastatic Breast Cancer Treated With Trastuzumab. PubMed 31754298
- Anticancer Drugs, 2019 (first author): Pharmacokinetics of pertuzumab administered concurrently with trastuzumab in Chinese patients with HER2-positive early breast cancer. PubMed 31305270
- Chin J Cancer Res, 2017 (senior author): Efficacy and safety of duloxetine in Chinese breast cancer patients with paclitaxel-induced peripheral neuropathy. PubMed 29142460
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion